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Abstract
For over fifty years, the methylation of mammalian actin at histidine 73 (actin-H73me) has been 
known to exist1. Beyond mammals, we find that actin-H73me is conserved in several additional 
model animal and plant organisms. Despite the pervasiveness of H73me, its function is enigmatic, 
and the enzyme generating this modification is unknown. Here, we identify SETD3 (SET domain 
protein 3) as the physiologic actin histidine 73 methyltransferase. Structural studies reveal that an 
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extensive network of interactions clamps the actin peptide on the SETD3 surface to properly orient 
H73 within the catalytic pocket and facilitate methyl transfer. H73me reduces the nucleotide 
exchange rate on actin monomers and modestly accelerates actin filament assembly. Mice lacking 
SETD3 show complete loss of actin-H73me in multiple tissues and quantitative proteomics singles 
out actin-H73 as the principal physiologic SETD3 substrate. SETD3 deficient female mice have 
severely decreased litter sizes due to primary maternal dystocia that is refractory to ecbolic 
induction agents. Further, depletion of SETD3 impairs signal-induced contraction in primary 
human uterine smooth muscle cells. Together, our results identify the first mammalian protein 
histidine methyltransferase and uncover a pivotal role for SETD3 and actin-H73me in the 
regulation of smooth muscle contractility. Our data also support the broader hypothesis where 
protein histidine methylation acts as a common regulatory mechanism.
SETD3, a ubiquitously expressed protein, is epigenetically up-regulated in response to 
muscle loading and hypertrophy2. SETD3 contains an N-terminal SET domain and a C-
terminal domain homologous to a Rubisco large subunit methyltransferase (LSMT) 
interaction domain (Extended Data Fig. 1a). Proteins containing the catalytic lysine 
methyltransferase SET domain are found in all three kingdoms of life and regulate diverse 
biological and pathologic processes3. In humans, ~half of the fifty-five SET family members 
methylate lysines on histone and/or non-histone protein substrates3. Enzymatic activities for 
the remainder of human SET proteins, including SETD3, are unclear. SETD3 was reported 
to methylate histone H3 at lysines 4 and 364. However, this conclusion was based on mass 
spectrometry data wherin mass shifts were inconsistent with a bona fide methylation event 
(see Figure 2C in4). When we tested SETD3 activity, it did not methylate histones in 
contrast to two established protein lysine methyltransferases (PKMTs), NSD2 and MLL23 
(Fig. 1a and Extended Data Fig. 1b). Based on these results and the cytoplasmic localization 
of SETD3 (Extended Data Fig. 1c), we conclude that SETD3 is not a histone 
methyltransferase and likely targets a non-histone substrate.
Among active PKMTs, SETD3 is most similar to human SETD65. We generated a putative 
SETD3 catalytic mutant based on this homology (Extended Data Fig. 1a) and performed in 
vitro methylation assays with 3H-SAM (S-adenosyl-methionine) on total cytoplasmic extract 
with wild-type or mutant SETD3. A ~42 kDa band was more prominent in reactions with 
wild-type SETD3 relative to the mutant (Fig. 1b). A three-step fractionation protocol was 
used to partially purify the SETD3-dependent activity for mass spectrometry analysis 
(Extended Data Fig. 1d-g). The ten most abundant hits in the proteomic dataset with 
molecular weights close to the candidate substrate (Extended Data Fig. 1h; Supplementary 
Table 1) were expressed as recombinant proteins and directly tested as SETD3 substrates in 
vitro (Fig. 1c). Of these proteins and other potential substrates, only beta-actin was 
methylated by SETD3 (Fig. 1c, Extended Data Fig. 1i). SETD6 and 10 additional active 
PKMTs do not methylate actin (Fig. 1d-e; Extended Data Fig. 1j). Also, SETD3 does not 
methylate the SETD6 substrate RelA (Fig. 1d)6. These data identify SETD3 as the first 
example of an enzyme to methylate actin in vitro.
To identify the specific actin residue/s modified by SETD3, in vitro methylated actin was 
analyzed by tandem mass spectrometry (MS/MS); deuterated SAM was used as the methyl 
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donor to distinguish SETD3-catalyzed methylation from all other sources. Unexpectedly, no 
lysine methylation events on actin were observed (Extended Data Fig. 2). We therefore 
extended the analysis to search for methylation events at other residues (arginine, glutamine, 
cysteine and histidine) and unambiguously identified incorporation of a single deuterated 
methyl moiety at histidine 73 of actin (Extended Data Fig. 3a-c). Histidine methylation is 
known to exist on a limited number of proteins. The only known histidine methyltransferase 
is the yeast enzyme Hpm1p, which methylates Rpl3 (not actin) and bears no structural 
resemblance to SETD37,8. However, methylation of actin at histidine 73 (actin-H73me) is a 
canonical modification present in mammals but not in yeast1,7,9. We identified H73me (or 
equivalent) on actin purified from ten different model organisms ranging from worms to 
plants to humans, which all have a SETD3 homologue, but not in S. cerevisiae, which lacks 
SETD3 (Extended Data Fig. 4). Thus, actin-H73me is an evolutionarily conserved 
modification present in a broad range of multicellular eukaryotic organisms.
Mutation of actin H73 to alanine (H73A) prevents methylation by SETD3 (Fig. 2a). 
Histidine can potentially be methylated on the nitrogen in position 1 (π, N1) or 3 (τ, N3) of 
the imidazole ring (Fig. 2b), with His(3-me) the physiologic modification found on 
endogenous actin. Methylation assays performed on actin peptides spanning H73 (residues 
66-80 of beta-actin) and in which H73 was either unmethylated or methylated at the N1 or 
N3 position (Extended Data Fig. 3d) showed that SETD3 methylated the unmodified peptide 
(kcat 0.4 min−1) and the peptide harboring H73(1-me) (with a much slower rate), but not 
H73(3-me), indicating that SETD3 catalyzes methylation of H73 at the physiologically 
relevant N3 position (Fig. 2c; Extended Data Fig. 3e-g).
To gain insight into the molecular basis of how SETD3 methylates a histidine substrate, we 
co-crystallized SETD3 with an actin peptide (residues 66-80) containing H73 in the 
presence of S-adenosyl-L-homocysteine (SAH). We obtained three highly similar crystal 
forms, focusing on the highest resolution structure of 1.69 Å (Extended Data Table 1). 
SETD3 contains two lobes (SET and LSMT-like) forming a V-shaped cleft (Extended Data 
Fig. 5a). The 15-residue actin-peptide occupies an extended surface groove of the SET-
domain (Fig. 2d), with H73 inserted into the active-site channel positioned to meet SAH 
from the other end (Fig. 2e). From the viewpoint of the cofactor-binding pocket, the methyl-
accepting H73 N3 atom is seen at the bottom of the channel (Extended Data Fig. 5b). 
Structural superimposition comparing SETD3 and SETD65 reveals that for SETD3, the 
methyl donor group of SAM points toward and is within the distance of 1.8 Å of the target 
N3 atom of the imidazole ring (Fig. 2f). An intra-molecular hydrogen bond between the 
main-chain carbonyl oxygen of E72 and the main-chain amide nitrogen of I75 bends the 
peptide substrate in a sharp turn at H73. This configuration allows H73 and G74 (the 
smallest residue) to enter deep into the channel and positions the target N3 atom in line with 
the methyl group and sulfur atom of SAM (Fig. 2f; Extended Data Fig. 5c-d); a linear 
arrangement comprising the nucleophile, the methyl group and the leaving thioester group in 
the transition state is required for the SN2 reaction mechanism used by SAM-dependent 
methyltransferases10.
All 15 residues of the actin peptide are bound in the structure (Fig. 2d; Extended Data Fig. 
5d), with the SETD3-actin peptide interface consisting of an extensive network of charged/
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polar and hydrophobic interactions involving both inter- and intra-molecular contacts 
(Extended Data Fig. 5d-n). For example, W79 and I71 of actin each fit into hydrophobic 
pockets on the SETD3 surface (Fig. 2g). This long and ordered peptide-substrate recognition 
groove for SETD3 is unique compared to other SET domains11, suggesting that SETD3 
would inefficiently accommodate substrates diverging from actin. Structure-guided point 
mutations in actin that disrupt the hydrophobic interaction (I71A) or are predicted to 
interfere with proper positioning of H73 in the catalytic pocket (G74I) impair the ability of 
SETD3 to methylate actin-H73, and the double mutant (I71A/G74I) abolishes activity (Fig. 
3a). Further, while a W79E substitution is tolerated (Extended Data Fig. 5e), SETD3 has no 
activity on actin I71A/W79E double mutations (Fig. 3a). These data highlight the sensitivity 
of SETD3 activity on actin to changes in the sequence spanning H73. Indeed, the fifteen-
residue sequence spanning H73 is highly conserved amongst the six human actin 
isoforms9,12 with the only difference being an I/V variation at position 76 that does not 
impact SETD3 recognition (Extended Data Fig. 5g,o). Accordingly, all actin isoforms are 
methylated by SETD3 in vitro (Fig. 3b). Finally, the putative SETD3 catalytic mutant is a 
conserved tyrosine (Y312) that participates in forming the active-site pocket (Extended Data 
Fig. 5d,i,p). This mutant has residual activity; however, mutation of additional conserved 
residues important for SAM binding abolished SETD3 activity (Fig. 3c; Extended Data Fig. 
5p).
We next raised a state-specific actin-H73me antibody that selectively recognized H73(3-me) 
peptides (Extended Data Fig. 6a). The majority of endogenous actin is marked by H73 
methylation in HT1080 cancer cells and the depletion of endogenous SETD3 by two 
independent single guide RNAs (sgRNAs) results in almost complete loss of this 
modification as determined by Western blotting and mass spectrometry (Fig. 3d; Extended 
Data Fig. 6b). We also observed complete loss of actin-H73me in a clonal HeLa cell line in 
which the SETD3 alleles were disrupted (Fig. 3e; Extended Data Fig. 6c). Further, 
complementation of SETD3-depleted HT1080 cells with CRISPR-resistant wild-type, but 
not catalytically-dead SETD3NHY, reconstituted actin methylation at H73 (Fig. 3f; Extended 
Data Fig. 6d). To assess the physiologic role of SETD3 in regulating actin H73 methylation, 
we obtained Setd3+/− mice from the Canadian Mouse Mutant Repository13 and generated 
Setd3 null homozygotes (Setd3−/−), which are viable. Analysis of actin purified from nine 
different tissue types isolated from Setd3+/+ and Setd3−/− mice showed that in tissues 
expressing SETD3, the majority of actin is methylated, however, this modification is not 
detected in any tissue from SETD3 deficient mice (Fig. 3g; Extended Data Fig. 7a-d). 
Finally, quantitative profiling of serum amino acids identified depletion of 3-methyl histidine 
as the lone abnormality in Setd3−/− mice (Extended Data Fig. 7e). Collectively, these results 
identify SETD3 as the physiologic actin-H73 methyltransferase.
Actin is one of the more abundant proteins in the human proteome and H73me is a high 
stoichiometry event. Our data argue that SETD3 is the principal enzyme tasked with 
generating actin-H73me, however is actin-H73 the only SETD3 substrate or one of many 
substrates? There are few known histidine methylated proteins besides actin – one is myosin, 
which SETD3 does not methylate (Fig. 3h). In addition, SETD3 has no activity on histones 
and several other proteins (see Fig. 1c-d and Extended Data Fig. 1i). To investigate SETD3 
catalytic specificity in a physiologic and unbiased setting, we used quantitative proteomics 
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to compare the methylome of HeLa cells ±SETD3 (see Fig. 3e). Of the >900 methylation 
events detected in the analysis, including ~180 histidine methylated peptides 
(Supplementary Table 2), actin-H73me was the only modification quantitatively altered 
upon SETD3 depletion (Fig. 3i). Together, these results argue that the principal physiologic 
enzymatic function of SETD3 is actin-H73 methylation.
Based on elegant studies leveraging actin mutants, H73 and its methylation are suggested to 
influence actin polymerization dynamics, in part due to its proximity to the ATP binding 
site9,12,14. However, a direct side-by-side comparison of the properties of actin ±methylation 
has not previously been possible. We purified actin ±H73me (Extended Data Fig 8a-b) from 
HeLa cells (see Fig. 3e) and found that methylation promoted actin polymerization kinetics 
in vitro but did not affect depolymerization (Fig. 4 a; Extended Data Fig. 8c). Moreover, the 
rate of ATP nucleotide exchange was faster with the unmethylated species (Fig. 4b). We note 
that actin-H73me exhibited a subtle increase in polymerization when extending off of 
phalloidin-actin seeds, and made little difference on polymerization rates in response to 
Arp2/3 stimulation (Extended Data Fig. 8d-e). To explore the role of H73 methylation 
during actin polymerization in cells, mouse embryonic fibroblasts (MEFs) were isolated 
from Setd3+/− mice positive for actin-H73me and Setd3−/− mice lacking methylation (Fig. 
4c). Cells containing actin-H73me were modestly more efficient at migration than cells 
deficient for methylated actin (Fig. 4d; Extended Data Fig. 8f). Together, these data are 
consistent with a model where SETD3 methylation of actin positively regulates actin 
polymerization in cells.
While Setd3−/− MEFs show a defect in cell migration, Setd3−/− mice are viable. Thus, actin-
H73me must play a specialized physiologic role in vivo that is not essential for basal actin 
functions. The characterization of SETD3 knockouts by the International Mouse Phenotypic 
Consortium scored several phenotypes, including moderate skeletal muscle myopathy, 
abnormal cardiac EKG, and mild decreased lean mass13. We did not observe gross 
histopathologic changes in muscle tissue from young adult Setd3−/− mice (Extended Data 
Fig. 9a-b). While we have not performed a comprehensive phenotypic analysis, we have 
observed that the litter size of female Setd3−/− mice, regardless of the genotype of the sire, 
are significantly smaller than litters from Setd3+/+ and Setd3+/− females (Extended Data Fig. 
9c). To explore this observation further, we analyzed parturition in Setd3−/− or littermate 
control females all sired by wild-type males. Normal parturition was defined as birth at 19 
days post-coitum (dpc) and dystocia (delayed parturition) was defined as either no births 
(≥20 dpc) or incomplete delivery with fetuses remaining in utero (≥20 dpc). Dystocia, a rare 
phenotype, was observed in 8/9 Setd3−/− mice, whereas normal parturition was observed in 
all of the control mice (Fig. 5a). As expected, in control mice, no fetuses were detected in 
utero at 20 dpc (Fig. 5b). In contrast, Setd3−/− females typically had many fetuses remaining 
in utero at ≥20 dpc (Fig. 5b-c).
The dystocia observed in the Setd3−/− females is independent of the genotype of the fetus as 
(1) wild-type males were used as sires, (2) pups successfully born to Setd3−/− mice were 
viable, and (3) Setd3+/− females had normal parturition. Thus, the cause of dystocia is of 
maternal origin. Secondary maternal dystocia is unlikely as there were no obvious and 
consistent anatomical pelvic abnormalities present in Setd3−/− females, and an anatomic 
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defect would not explain the presence of intact fetuses in utero. Thus, the dystocia is 
primary, either due to abnormal myometrium contraction or a defect in hormone signaling. 
To distinguish between these possibilities, early labor was induced in wild-type and Setd3−/− 
females with oxytocin administration at 18 dpc (see schematic Fig. 5d). Wild-type mice 
went into early labor and all pups were born within 24 hours of treatment, whereas the 
dystocia of Setd3−/− mice was refractory to oxytocin (Fig. 5e-f). Similar results were 
observed with prostaglandin treatment as an independent ecbolic agent15 (Extended Data 
Fig. 9d-e). These data identify a specific requirement for SETD3 in the contraction 
mechanism of the laboring uterus, a mechanism that fundamentally relies on proper actin 
behavior16.
As multiple, unique point mutations in actin are implicated in the etiology of several human 
smooth muscle myopathies17,18, we postulated a link between actin-H73me and uterine cell 
contraction in the primary dystocia of Setd3−/− females. To test this idea, we depleted 
SETD3 and actin-H73me from primary human myometrial cells (Fig. 5g) and measured 
cellular contraction under normal conditions and in response to two uterine smooth muscle 
contraction stimulants. While depletion of SETD3 had only a marginal impact on intrinsic 
contraction, the absence of SETD3 significantly impeded signal-induced contraction by 
oxytocin and Endothelin-1 (Fig. 5h-i). Finally, the loss of Endothelin-1-induced cellular 
contraction upon SETD3 knockdown was rescued in the primary human myometrial cells by 
complementation with CRISPR-resistant wild-type SETD3, but not by catalytically inactive 
SETD3NHY (Fig. 5j-k; Extended Data Fig. 9f). These data suggest a specific role for actin-
H73me in signal-induced contraction of smooth muscle.
Here, we have identified SETD3 as the first known metazoan protein histidine 
methyltransferase and the enzyme responsible for generating the abundant and enigmatic 
actin-H73me. SETD3 represents the first SET domain family member to methylate a residue 
besides lysine, broadening the current framework of possible chemistries catalyzed by SET 
domains. Our analysis revealed histidine methylation – previously detected on only a 
handful of proteins – to be surprisingly common, observed with a frequency similar to that 
of protein lysine di- and tri-methylation19. Actin mutations are implicated in smooth muscle 
myopathies (e.g. 17,18) including a case of a pregnant patient suffering from uterine muscle 
atony20. We postulate that SETD3 deficiency and loss of H73me presents like intrinsic actin 
mutations by altering actin responsiveness to polymerization cues, which leads to defects in 
smooth muscle contraction. H73me impact on actin-myosin interactions is marginal 
(Extended Data Fig. 9g-h), suggesting smooth muscle contraction regulation is mediated by 
a different mechanism. Specifically, besides the canonical actin-myosin pathway, there is a 
distinct role for dynamic actin polymerization in mediating mechanical force generation of 
smooth muscle21. In summary, our work identifies a functional role for mammalian histidine 
methylation in regulating actin and smooth muscle contraction and suggests a broad role for 
this modification in the regulation of mammalian proteomes.
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Methods
Reagents.
Biotinylated peptides were synthesized at the UNC High-Throughput Peptide Synthesis and 
Array Facility (Chapel Hill, NC)22. Fmoc-L-histidine amino acids with either (1-me) or (3-
me) modifications (Sigma-Aldrich) were used in the synthesis of these peptides and 
synthesized peptides were purified by HPLC (>92% purity). Antibodies used in this study: 
SETD3 (Abcam), pan-actin (Cytoskeleton), beta-tubulin (Millipore), H3K4me2 (Cell 
Signaling), H3K36me2 (Cell Signaling), H73(3-me) see below, GFP (Invitrogen), Alexa488 
anti-rabbit antibody (Life Technologies), anti-rabbit and anti-mouse peroxidase conjugated 
antibodies (Jackson Immunoresearch). Western blots were visualized by chemiluminescence 
(GE Healthcare).
Anti-H73(3-me) specific antibody generation.
Peptide corresponding to beta-actin amino acids 68-78 (KYPIEHGIVTN) with H(3-me) 
installed at position 73 was synthesized and HPLC purified (99% purity). This peptide was 
conjugated to KLH and used as antigen to immunize rabbits. Rabbit protocols, peptide 
conjugation, immunization, and antiserum production were performed by Pocono Rabbit 
Farm & Laboratory (Canadensis, PA). Antiserum was negatively selected against 
unmodified actin peptide (amino acids 66-80). Final purification with was performed with 
immobilized antigenic peptide to select for H73(3-me) specific antibodies.
Recombinant protein expression for in vitro reactions.
SETD3 (Q86TU7) and actin were cloned into pGEX-6P-1. MLL2 catalytic complex 
contained GST-tagged catalytic SET domain of MLL2, and full-length, 6xHis-tagged 
ASH2L, WDR5, DPY30, and RBBP5 that were all individually expressed in bacteria and 
assembled in stoichiometric proportions to result in a catalytic complex23. Lysine 
methyltransferases used as controls were reacted with previously reported substrates24-35. 
Candidate substrate cDNAs were subcloned from the human ORFeome (Open Biosystems) 
using an LR recombination reaction (Life Technologies) into pDEST15. Mutations of all 
proteins were generated using Phusion site-directed mutagenesis (Thermo Scientific) 
according to manufacturer’s recommendations. All proteins were expressed as N-terminal 
GST fusions (except for non-catalytic MLL complex components) in BL21 or BL21(DE3) 
codon plus bacteria. Expression was performed at 16°C overnight in the presence of 0.1 mM 
IPTG. Recombinant GST fusions were purified with Glutathione Sepharose 4B (GE 
Healthcare) and eluted in 100 mM Tris pH 8.0, 10 mg/ml reduced glutathione (Sigma-
Aldrich). Any cleavage of GST tags was performed with Prescission protease (GE 
Healthcare) overnight at 4°C. Recombinant 6xHis-tagged proteins were purified with Ni-
NTA agarose (Life technologies) and eluted in 100 mM Tris pH 8.0, 250 mM imidazole. 
Kinetics experiments and crystallography utilized additional purification described below.
Purification of SETD3 for crystallography.
SETD3 was expressed as a GST-fusion as described above. Cleared bacterial lysate 
containing soluble glutathione S-transferase (GST) fusion SETD3 was first loaded on a self-
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packed glutathione-sepharose column and eluted with buffer containing 100 mM Tris (pH 
8.0), 150 mM NaCl, 5% glycerol, 0.5 mM TCEP and 20 mM reduced glutathione. The GST 
tag was removed by ~100 μg prescission protease (purified in-house) at 4°C overnight. The 
cleaved protein solution was diluted to ~50 mM NaCl and further purified by HiTrap Q-HP, 
GE Healthcare) with a linear gradient of 50 mM to 500 mM NaCl; SETD3 eluted together 
with the cleaved GST around 200-300 mM NaCl. To remove GST, fractions were loaded 
onto a fresh glutathione-sepharose column and the flow-through was collected and 
concentrated to ~2 ml. SETD3 was then further purified by size exclusion chromatography 
(Superdex 200, GE Healthcare) in 20 mM Tris (pH 8.0), 200 mM NaCl, 5% glycerol, 0.5 
mM TCEP. All purification steps were performed at 4°C. The chromatography was 
conducted in a BIO-RAD NGCTM system.
Cellular fractionation.
Cytoplasmic cellular extracts were prepared by established protocols36. Briefly, cells were 
disrupted by hypotonic lysis (25 mM KCl, 1.5 mM MgCl2, 10 mM HEPES–KOH pH 7.9, 
protease inhibitors) and dounce homogenization. Size exclusion chromatography (Superose 
6) was performed in hypotonic lysis buffer. Ion-exchange chromatography (Sepharose Q 
HP) columns were equilibrated in hypotonic lysis buffer and proteins were eluted on a linear 
gradient from 25-600 mM KCl. Fractions were concentrated with centrifugal filter units 
(Amicon, 3000 Da MWCO) before being used as substrate in in vitro reactions with 
radiolabeled SAM. Chromatography for substrate enrichment was performed with an AKTA 
FPLC (GE Healthcare)
In vitro methylation reactions.
In vitro methyltransferase reactions were performed with 5 μg methyltransferase, 1 μg 
substrate, and 2 μCi 3H-S-adenosylmethionine (American Radiolabeled Chemicals) in a 
buffer containing 50 mM Tris pH 8.0, 20 mM KCl, 5 mM MgCl2 at 30°C overnight. 
Reactions were resolved by SDS-PAGE, and 3H-methylation was visualized by 
autoradiography and gels were stained with Coomassie as a loading control. Reactions with 
deuterated SAM (CDN Isotopes) or normal SAM (Sigma-Aldrich) were performed with 
SAM at a final concentration of 80 μM.
Steady-state kinetic measurement.
Human beta-actin peptide (residues 66-80; TLKYPIEHGIVTNWD) was used as a substrate 
for SETD3. The reaction mixture containing 20 mM Tris (pH 8.0), 50 mM NaCl, 0.1 mg/ml 
BSA, 1 mM DTT, and 0.18 μM SETD3. To determine the Km value for peptide, the 
concentration of S-adenosyl-L-methionine (SAM) was kept constant at 40 μM, while for 
determination of the Km for SAM, peptide concentration was kept constant at 50 μM. 
Reactions were carried out at room temperature for 20 min with a total volume of 20 μl, and 
terminated by the addition of trifluoroacetic acid (TFA) to 0.1% (v/v). The activity of 
SETD3 was measured using a bioluminescence assay (MTase-Glo™, Promega) in which the 
reaction by-product S-adenosyl-homocysteine (SAH) is converted into ATP in a two-step 
reaction and can be detected via a luciferase reaction37. In general, 5 μl of reaction mixture 
was transferred to a low-volume 384-well plate and the luminescence assay was performed 
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according to the manufacture’s protocol. A Synergy 4 Multi-Mode Microplate Reader 
(BioTek) was used to measure luminescent signal.
Time-course of methylation for three β-actin peptides.
Typically, a reaction mixture contained 20 mM Tris (pH 8.0), 50 mM NaCl, 0.1 mg/ml BSA, 
1 mM DTT, 40 μM SAM and 50 μM peptide. In addition to the unmodified peptide, 1-
methyl-His and 3-methyl-His peptides were used in the activity assay. For unmodified 
peptide, 0.18 μM SETD3 was used, while for modified ones, 80-fold higher amounts of 
SETD3 (14.4 μM) were used due to very low activity on these peptides. For each time point, 
10 μl of reaction mixture was taken and adding TFA to 0.1% stopped the reaction. The 
luminescence assay was performed as described above.
Mass spectrometry.
LC-MS/MS was performed using an Orbitrap Elite or Fusion (Thermo Scientific) and data 
was analyzed manually or using MaxQuant software38. Peptide identification searches with 
MaxQuant were performed with parameters to identify methionine oxidation, N-acetylation, 
monomethyl lysine, dimethyl lysine, trimethyl lysine, methyl histidine, monomethyl 
arginine, dimethyl arginine, methyl glutamine, and methyl cysteine. in vitro reactions were 
directly resolved by SDS-PAGE before mass spectrometry analysis was performed as above 
and digested with trypsin, chymotrypsin or Glu-C (Promega). Quantitative proteomic 
analysis was performed with SILAC, light isotopic labels (K0R0) and heavy isotopic labels 
(K8R10). In the SETD3-dependent methylomics, no peptides with a SILAC ratio greater 
than 1.5 were deemed to be SETD3-dependent methyl events. No peptides (other than actin) 
with at least a 1.5-fold ratio in the reverse direction and NaN ratio in the forward direction 
were identified at all in the forward direction. Actin H73 methylation was detected with light 
(WT cells, K0R0) labeling in the forward direction and not with heavy labeling (SETD3 
knockout cells, K8R10). We thus concluded that the lack of a calculable ratio (light/heavy) 
in the forward direction is due to the clonal nature of the cell lines being used. We therefore 
plotted the forward ratio as infinite (Fig. 3i).
Targeted quantification of actin methylation was performed by manual identification of 
methylated and unmethylated peptides followed by integration of area under the curve for 
chromatographic peaks associated with the corresponding m/z. Percentage of methylated 
peptides was determined as a fraction of the sum total area for methylated and unmethylated 
species. Actin was isolated from cellular or tissue sources using DNAse I affinity 
chromatography39. DNAse I was immobilized to NHS-activated Sepharose FF (GE 
Healthcare) overnight in 100 mM Hepes pH 7.5, 150 mM NaCl, 80 mM CaCl2. Cells/tissues 
were homogenized with buffer containing 1M Tris pH 8.0, 600 mM KCl, 0.5 mM MgCl2, 
4% NP-40, 1% Tween-20, 1 mM DTT, 1 mM ATP, and protease inhibitors40 (Roche). 
Cleared lysates were incubated with immobilized DNase I resin overnight, washed, boiled in 
SDS sample buffer, and purified actin was resolved by SDS-PAGE. Gels were silver-stained 
(Thermo Scientific) then actin bands were excised and processed for mass spectrometry by 
in-gel digest with sequencing grade trypsin. The following sources were used in the analysis 
of actin methylation across evolution: S. cerevisiae, mid-log BY4741; A. thaliana, leaf 
tissue; N. benthamiana, leaf tissue; C. elegans, mixed population; D. melanogaster, larvae; S. 
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frugiperda, Sf9 cells; D. rerio, 5 days post fertilization embryos; X. laevis, egg extract; G. 
gallus, skeletal muscle; M. musculus, brain/uterine/skeletal muscle tissue; H. sapiens, cell 
lines.
Crystallography.
Crystallization of the SETD3-SAH-actin peptide (residues 66-80; Genscript) complex was 
carried out by the hanging-drop vapor-diffusion method at 20°C after mixing SETD3 (~15 
mg/ml) with SAH and peptide at a molar ratio of 1:4:5, and then mixed with an equal 
amount of well-solution. Three different crystal forms were obtained. Crystals with space 
group P21 were obtained with 0.2 M ammonium acetate, 0.1 M sodium citrate tribasic 
dihydrate pH 5.6, and 30% (w/v) polyethylene glycol 4000. Crystals with space group 
P212121 were obtained with two similar conditions, either 0.2 M ammonium sulfate or 0.2 
M sodium chloride, 0.1 M BIS-TRIS pH 5.5, 25% (w/v) polyethylene glycol 3350, and 0.1 
M BIS-TRIS pH 5.5, 25% (w/v) polyethylene glycol 3350. The first form, like the P21 
crystal, contained two SETD3-SAH-peptide complexes per asymmetric unit, while the 
second contained only one complex.
For X-ray diffraction data collection, single crystals were flash frozen in liquid nitrogen by 
equilibrating in a cryoprotectant buffer containing well solution with 25% (v/v) ethylene 
glycol. All datasets were collected at the SER-CAT beamline 22ID of Advanced Photon 
Source at Argonne National Laboratory. Crystallographic datasets were processed with 
HKL200041. Molecular replacement was performed with PHENIX PHASER module42 by 
using the structure of human SETD3 in complex with SAM (PDB ID 3SMT) as a search 
model. PHENIX REFINE43 was used for refinement with 5% randomly chosen reflections 
for validation by the Rfree value. COOT44 was used for peptide building and model 
corrections between refinement rounds. Structure quality was analyzed during PHENIX 
refinements and later validated by the PDB validation server. Molecular graphics were 
generated using PyMol (Schrödinger, LLC).
We note that the high-resolution data at 1.69 Å (PDB 6MBK) were the result of merging two 
datasets collected from two different parts of the same crystal. This crystal did diffract X-
rays to higher resolution but was susceptible to radiation damage, especially in the higher 
resolution range. The merge resulted in 98.4% completeness in the highest resolution shell 
of 1.75-1.69 Å. The somewhat higher R-work and R-free values of the structure (PDB 
6MBK) might be an indication of radiation damage that could not be modeled and further 
refinement would not lower these R values substantially and the structure and map compared 
well with the quality of the other two crystal forms.
Actin purification for biochemical assays.
Actin was purified from wild-type HeLa cells or a clonally-derived HeLa cell line in which 
SETD3 was knocked out. Purification was adapted from established protocols45. Briefly, 
HeLa cells were resuspended in lysis buffer (10 mM Tris–HCl, pH 8.0, 11.6 % (w/v) 
sucrose, 1 mM EGTA, 1 mM ATP, 5 mM (DTT), and protease inhibitor cocktail) and lysed 
by sonication. Lysates were cleared by ultracentrifugation (100,000 × g, 2 hours). Cleared 
cellular extract was loaded onto an anion-exchange column (Sepharose Q HP, GE 
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Healthcare) equilibrated with column buffer (10 mM Tris–HCl, pH 8.0, 0.2 mM CaCl2 , 0.5 
mM ATP, 0.5 mM DTT). Actin protein was eluted on a linear gradient of column buffer 
containing 0 mM KCl to column buffer containing 600 mM KCl. Actin-positive fractions 
were polymerized with 2 mM MgCl2 and 1 mM ATP at room temperature, and polymerized 
actin was pelleted at 100,000 × g for 2 hours. F-actin was resuspended and depolymerized in 
2 mM Tris pH 8.0, 0.2 mM CaCl2, 0.5 mM DTT, and 0.2 mM ATP for ≥ 2 days. Residual F-
actin was cleared by ultracentrifugation as before and the protein in the supernatant was used 
in biochemical assays.
Pyrene-based polymerization assays were performed according to commercially available kit 
instructions (Cytoskeleton). Purified HeLa actin was combined in a 10:1 ratio with pyrene-
labeled actin from rabbit skeletal muscle (Cytoskeleton). Polymerization was induced with 2 
mM MgCl2, 50 mM KCl, and 1 mM ATP and monitored by fluorescence in a plate reader 
(excitation: 355 nm/emission: 410 nm, Biotek Cytation 3, Gen5 v3.04.17 software). 
Readings were taken every 60 seconds with orbital shaking. Depolymerization assays were 
performed by diluting actin polymerized as above 250-fold in 10 mM Tris pH 8.0, 0.2 mM 
CaCl2, 1 mM ATP. Depolymerization was monitored by fluorescence similar to 
polymerization. Phalloidin-actin seeds were made by polymerizing monomeric actin into 
filaments followed by incubation of the resulting F-actin with a stoichiometric excess of 
phalloidin (Millipore-Sigma). F-actin was pelleted for 1h at 100,000 × g. The F-actin was 
washed and resuspended in F-buffer (10 mM Tris pH 7.5, 2 mM MgCl2, 50 mM KCl, 1 mM 
ATP, 1 mM DTT) and then sheared through a 27G needle. Seeds were allowed to recover 
overnight at room temperature. Polymerization with seeds was performed with 2 μM seed, 1 
μM monomeric actin, and 0.1 μM pyrene-actin. Polymerization with Arp2/3 complex 
(Cytoskeleton) and recombinant WASP VCA (Cytoskeleton) were used at concentrations of 
5 nM and 100 nM respectively with 1 μM actin and 0.1 μM pyrene-actin.
Nucleotide Exchange.
Nucleotide exchange assays were performed as previously reported46. G-actin monomers 
were transferred into a buffer without ATP (2 mM Tris pH 7.5, 0.2 mM CaCl2, 1 mM DTT) 
by desalting column (GE Healthcare, PD spin column with G-25). 1,N6-ethenoadenosine-5’-
O-triphosphate (ε-ATP, Axxora) was added to G-actin at a final concentration of 0.3 mM 
and incubated on ice for at least 2h. Unbound ε-ATP was removed by desalting as before. 
ATP exchange of ε-ATP with normal ATP (100 μM) was performed with 2 μM G-actin and 
monitored by fluorescence (excitation, 340 nm; emission, 410 nm) in triplicate.
Cell culture.
293T (ATCC), HT1080 (ATCC) and H1-HeLa (ATCC) cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Life Technologies) supplemented with 10% Fetal 
bovine serum, 2 mM L-glutamine, and penicillin/streptomycin (Life Technologies). Primary 
uterine smooth muscle cells (ATCC) were cultured in vascular cell basal media (ATCC) 
supplemented with the vascular smooth muscle growth kit (ATCC). All above cell lines were 
authenticated and declared mycoplasma free by ATCC. Transfections were performed with 
either TransIT-293 or TransIT-LT1 (Mirus) in 293T cells or HT1080 cells, respectively. 
Stable cell lines were generated using lentiviral transductions. 293T cells were co-
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transfected with lentiviral plasmid, pCMV-Δ8.2 and pCMV-VSVg in a ratio of 9:8:1 by 
mass. 48 hours after transfection, target cells were transduced with 0.45 μm filtered viral 
supernatant supplemented with 8 μg/ml polybrene. Viral concentration was performed as 
necessary with Lenti-X lentiviral concentration solution per manufacturer’s 
recommendations (Takara). Cells were selected 24 hours after media replacement. To 
deplete cells of SETD3, CRISPR/Cas9 components were stably expressed in HT1080 cells 
using lentiCRISPRv2 (Addgene) with the following single guide RNAs: sgControl, 5’- 
CTTCGAAATGTCCGTTCGGT-3’; sgSETD3-1, 5’-TGTTACAGAATGCAGCAGTC-3’; 
sgSETD3-2, 5’-GTATGTGCAGATCCGGACTC-3’. sgSETD3-1 was used for reconstitution 
experiments and generation of the clonal H1-HeLa cell line. Cell selection was performed 
with 2 μg/ml puromycin or 100 μg/ml hygromycin. SETD3 cDNA cloned into pLenti CMV 
Hygro DEST (W117-1) (Addgene) was made CRISPR/Cas9-resistant by incorporating a 
synonymous mutation into the PAM sequence associated with sgSETD3-1 from CGG to 
CTG. Reconstitution experiments were performed by transient transfection in HT1080 cells 
or stable incorporation by lentivirus in primary uterine smooth muscle cells. SILAC cell 
culture was performed with DMEM for SILAC (Thermo Scientific), supplemented with 
10% dialyzed fetal bovine serum, 115 mg proline (Applichem), 50 mg lysine (light, lysine 
HCl [Applichem]; heavy, 13C6,15N2-L-Lysine HCl [Silantes]), and 50 mg arginine (light, 
arginine HCl [Applichem]; heavy, 13C6,15N4-L-Arginine HCl [Silantes]). Cells used for 
SILAC-based proteomics were cultured in SILAC media for at least one week before 
analysis.
Immunofluorescence imaging
H1-HeLa cells were seeded overnight onto autoclaved 12mm circle micro cover glass 
(VWR) at 50,000 cells per well in 24-well plates (Greiner Bio-One). Samples were fixed 
with 4% paraformaldehyde (Sigma) for 30 minutes at room temperature. Each sample was 
incubated with Anti-GFP antibody (1:300) in immunofluorescence blocking buffer (1× 
phosphate buffered saline (PBS) with 3% BSA, 1% saponin and 1% Triton X-100) overnight 
at 4°C. Cells were washed thoroughly with 1xPBS and then incubated for 1 hour at room 
temperature with Alexa488 anti-rabbit antibody (1:500) and DAPI stain (Insitus 
Biotechnologies, 1:300 dilution) in immunofluorescence blocking buffer. Washed micro 
cover glasses were then mounted onto microscope slides (Fisher Scientific) using 
Vectashield with DAPI (Vector Laboratories Inc). Images were taken with Zeiss LSM 700 
confocal microscope and processed with Volocity software.
MEF cell line generation.
Embryos were harvested 13.5 dpc and internal organs were removed. Remaining embryos 
were minced and treated with trypsin to dissociate cells for 30 minutes at 37°C. 
Trypsinization was quenched with growth media (DMEM+10% fetal bovine serum). 
Quenched cell suspension was plated and allowed to grow for 4 days. At this point, cells 
were frozen or used in experiments. Genotyping of new cell lines were performed with 
residual embryonic tissue and confirmed by western blot analysis.
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Cell Migration assays.
Cell migration assays were performed with Radius cell migration kits (Cell Biolabs). MEFs 
(1×105 cells) were plated in 24-well migration plates and allowed to attach overnight. The 
Radius gel was removed according the manufacturer’s protocol. After gel removal, imaging 
was performed over a 24h period with a Nikon Eclipse Ti inverted fluorescent microscope 
and NIS elements (version 4.60) software. During image acquisition, the environmental 
conditions were kept at 5% CO2 and 37°C (Okolab). After the 24 hour period, cells were 
fixed and stained with DAPI according to kit instructions. Cell migration was quantified by 
re-imaging migration fields and counting DAPI-stained nuclei within the boundary of the 
circular void left by the gel at 0h. Migration assays were performed in triplicate.
Cell Contraction assays.
Cellular contraction assays were performed on a collagen substrate (Cell Biolabs). 450 μl 
collagen mixture made with the provided 5xPBS was added to a 24-well plate and allowed 
to polymerize according to the manufacturer’s protocol. Primary uterine smooth muscle 
cells (5×104 cells) were layered on top of a collagen matrix in vascular basal medium 
without the growth kit. Cells were allowed to attach to the collagen overnight at 37°C. The 
next day, the collagen disks were released from the sides of each well. Induction of 
contraction was performed with 10 μM oxytocin (Tocris) or 1 μM Endothelin-1 (Tocris). 
Contraction was monitored by imaging after 24h of contraction. Quantification of collagen 
disk area was performed in ImageJ (NIH). Relative disk area was determined by normalizing 
to the area of disks lacking cells. All assays were performed in triplicate.
Ethics statement
Mice were housed in the Stanford mouse facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care. All experiments were approved 
by Stanford’s Institutional Animal Care and Use Committee.
Maintenance of mouse colonies.
Husbandry is performed in accordance with the Guide for the Care and Use of Laboratory 
Animals, 8th edition (2010) and the 2015 revision of the Public Health Service Policy on 
Humane Care and Use of Laboratory Animals. Room conditions included a temperature of 
23°C, relative humidity of 30% to 40%, and a 12:12-h light:dark cycle (lights on, 0700 h). 
All mouse colonies are maintained under SPF conditions in irradiated disposable 
individually ventilated cages (InnocageR, Innovive, San Diego, CA) with irradiated, corncob 
bedding, irradiated food (Teklad 2918 Global 18% Protein Rodent Diet, Envigo) and UV-
irradiated, acidified (pH, 2.5 to 3.0), reverse-osmosis–purified bottled water (AquaviveR, 
Innovive). The mouse colonies are monitored for viral, bacterial, and parasitic pathogens 
using dirty-bedding sentinels that were tested quarterly and were found to be free of mouse 
parvovirus, minute virus of mice, mouse hepatitis virus, mouse rotavirus, Theiler’s murine 
encephalomyelitis virus, murine norovirus, Sendai virus, mouse adenovirus 1 and 2, 
ectromelia virus, lymphocytic choriomeningitis virus, pneumonia virus of mice, respiratory 
enterovirus III, fur mites, lice, and pinworms. Sample size was maximized as much as 
possible to gain highest confidence in the results. No randomization was necessary as only 
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single variables changed per experiment. Blinding was not necessary as any phenotypic 
assessment or other measurements was performed using discrete, quantitative measurements
Mouse Strains.
C57BL/6N - Setd3tm1.1(NCOM)Mfgc/Tcp heterozygous mice were obtained from the 
Canadian Mouse Mutant Repository (CMMR, Toronto, Canada). The strain was made at the 
Toronto Centre for Phenogenomics as part of the NorCOMM2 project using NorCOMM ES 
cells47. Progeny were genotyped using either the Setd3-McKerlie PCR assay to identify 
either the 212-bp wild-type band (primers: Setd3_wt_F1- 
AACCAGCAGTGCACAGAGACAAGCTG; Setd3_wt_R1 - 
AACCCAAACTCTGCCAGCCAAAGCAC) and/or a 566 bp tm1.1 band (primers: 
Setd3_tm1_F4- AAACTGGTGCTGCTGATAACCTGGGC; GH717 - 
CACCGACGCCAATCACAAACAC) following instructions provided by the CMMR or the 
use of a commercial genotyping service (Transnetyx, Memphis, TN). For timed pregnant 
matings, C57BL/6N male mice were purchased from Charles River Laboratories (Hollister, 
CA).
Quantification of litter size and length of gestation.
Quantification of pregnancies and litters for both trio or pair breeding females were 
tabulated for Setd3−/−, Setd3+/−, Setd3+/+ females. All litters that were observed 
(“confirmed”) were counted, even if pups subsequently died. To determine pups/litter, litters 
that were lost prior to when pups could be counted were listed as 0 pups for that litter. The 
length of gestation for Setd3−/−, Setd3+/−, Setd3+/+ females was determined by timed 
pregnant matings. Females were mated to wild type C57BL/6N males (Charles River 
Laboratories, Hollister, CA). Whether the female was a virgin (primigravida) or had a 
previous pregnancy (multigravida) was recorded. Presence of a vaginal plug was denoted 0 
day post coitum (dpc). Plugged females were moved to a separate cage and weights taken at 
intervals to confirm pregnancy. A few days prior to 19 dpc, the female was placed in a 
separate cage and provided with nesting material (Enviro-driR, Shepherd Specialty Papers) 
and a paper tube. Cages were checked for births twice daily (morning and afternoon) starting 
from 18 dpc.
Quantifying dystocia and fetuses in utero.
The day of parturition for Setd3−/− females varied from 19 dpc to ≥20 dpc. Normal 
parturition was defined as birth at 19 days post-coitum (dpc) and dystocia (delayed 
parturition) was defined as either no births (≥20 dpc) or incomplete delivery with fetuses 
remaining in utero (≥20 dpc). To determine whether Setd3−/− females that delivered on 19 
dpc still exhibited a delayed in parturition, females were euthanized on late 20 dpc if they 
did not deliver on 19 dpc (Setd3−/−) or 24h after giving birth if they delivered on 19 dpc 
(Setd3−/−, Setd3+/−, Setd3+/+) and examined for the presence of fetuses in utero. We note 
that the dystocia occurred in both primigravida and multigravida Setd3−/− females and that 
actin-H73me is not detected in the uterus of late-stage pregnant Setd3−/− females (data not 
shown).
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Induction of parturition.
Oxytocin (VetOneR, MWI Veterinary Supply Co.) was given subcutaneously on 18 dpc to 
induce preterm labor (dose = 0.4 U in 0.9% saline supplemented with 0.1% calcium 
gluconate and 0.025% dextrose, given 3x, q30 min over a period of 1.5 h) to Setd3−/−, and 
Setd3+/+timed-pregnant females. The normal day of birth for Setd3+/+mice of this strain is 
19 dpc. All pups born on 18 dpc were removed and euthanized. All mice quantified for 
fetuses in utero were euthanized at 1700h on d19.
A PGF2α cocktail (1 ml LutalyseR (5 mg PGF2α/ml), 1 ml 10% calcium gluconate, 0.05 ml 
of 50% isotonic dextrose, and 8.0 ml of 0.9% sterile saline) was used to induce parturition in 
two Setd3−/− females on 19 dpc. Females were injected subcutaneously with 1 ml of the 
cocktail at 3 time points on 19 dpc (~0900 h, ~1200 h, ~1700 h). The females were 
monitored for parturition and euthanized on late 20 dpc at 1700 h.
Metabolic analysis.
Amino acids were analyzed as underivatized compounds by liquid chromatography tandem 
mass spectrometry (LC-MS/MS). Samples (50μL) were deproteinized with 50μL of 6% 
sulfosalicylic acid, and centrifuged for 15 min at 17,000 RCF. Supernatants were diluted 
with an isotopic standard mixture (Cambridge Isotope Laboratories, Inc) in 2 μM 
tridecafluoroheptanoic acid (TDFHA), and then injected into the LC-MS/MS system. 
Samples were analyzed using a clinically validated amino acid analysis method48. An 
Agilent 1200 series liquid chromatography system equipped with a Thermo Hypercarb trap 
column (3 μm, 4.6 × 50 mm) and a Waters BEH C18 analytical column (2.5 μm, 2.1 × 100 
mm) was used to separate compounds in a trap and reverse-elute configuration. An Agilent 
6460 triple quadrupole mass spectrometer was used in positive polarity electrospray 
ionization for detection by dynamic multiple reaction monitoring (MRM). Mobile phase A 
was 0.02% perfluoroheptanoic acid and mobile phase B was acetonitrile. Standard curves 
were prepared by diluting amino acid standards (Wako Chemicals USA, Inc); for 1-
methylhistidine, S-aminoethylcystine was used as the internal standard and for 3-
methylhistidine, histidine-13C615N3 was used as the internal standard. Agilent Masshunter 
B08 was used for data analysis.
Muscle Tissue Histology.
Tissues were fixed by immersion in 10% neutral buffered formalin, routinely processed for 
paraffin embedding, and 5μm thick sections were routinely stained with hematoxylin and 
eosin (H&E).
Myosin expression and purification
Construction, expression, and purification of the wild-type recombinant human beta-cardiac 
myosin sS1 and the hypertrophic cardiac myopathy H251N mutant49 are described in detail 
elsewhere49-51. Briefly, a truncated version of MYH7 (residues 1–808), corresponding to 
sS1, with a C-terminal enhanced green fluorescent protein (eGFP), was co-expressed with 
myosin light chain 3 (MYL3), encoding human ventricular essential light chain (ELC), and 
containing an N-terminal FLAG tag (DYKDDDDK) and tobacco etch virus (TEV) protease 
site in mouse myoblast C2C12 cells using the AdEasy Vector System (Obiogene Inc.). The 
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myosin heavy chain with its associated FLAG-tagged ELC was first purified from clarified 
lysate with anti-FLAG resin (Sigma). After cleaving off the FLAG tag with TEV protease, 
the human beta-cardiac sS1 was further purified using anion exchange chromatography on a 
1-mL HiTrap Q HP column (GE Healthcare). Peak fractions were eluted with column buffer 
(10 mM imidazole, pH 7.5, ~200 mM NaCl, 4 mM MgCl2, 1 mM DTT, 2 mM ATP, and 
10% sucrose) and concentrated by centrifugation in Amicon Ultra-0.5 10-kDa cutoff spin 
filters (EMD Millipore) before being used in assays or stored at −80 °C.
in vitro motility.
Experiments were conducted following previously described methods51-54. Briefly, frozen 
myosin protein was first subjected to a “deadheading” procedure to remove inactive heads. 
Myosin was mixed with 5 – 10x molar excess of unlabeled F-actin on ice for 5 min, 
followed by addition of 2 mM ATP for 3 min, then centrifuged at 95k rpm in a TLA-100 
rotor (Beckman Coulter) at 4°C for 20 min. The supernatant was collected for use in the 
motility. Flow chamber was built on a nitrocellulose-coated coverslip mounted on a glass 
slide. Deadheaded myosin was immobilized via specific binding to the GFP antibody that 
non-specifically binds to the coverslip surface, followed by blocking with assay buffer (25 
mM imidazole pH 7.5, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 10 mM DTT, and 1 mg/ml 
BSA). A final solution containing fluorescently labeled bovine cardiac F-actin, 2 mM ATP, 
and an oxygen-scavenging system (0.4% glucose, 0.11 mg/ml glucose oxidase, and 0.018 
mg/ml catalase) was subsequently flowed in before imaging on a total internal reflection 
fluorescence microscope (Nikon Eclipse Ti-E) equipped with a 561 nm laser (Cobolt) and a 
100x oil-immersion objective (Nikon)55. Time-lapse movies were acquired at multiple fields 
of views for each experimental condition at 1 Hz sampling rate. Movies were analyzed using 
the FAST (Fast Automated Spud Trekker) software56 to obtain the mean velocities with 20% 
tolerance. All experiments were conducted at 23°C.
Actin-activated Myosin ATPase activity.
Purified actin was freshly cycled to F-actin by extensive (four times over 4 d) dialysis in 
ATPase buffer (10 mM imidazole, pH 7.5, 5 mM KCl, 3 mM MgCl2, and 1 mM DTT) to 
remove any residual ATP. The monomeric concentration of F-actin was determined by 
measuring the absorbance of a serial dilution of the actin in 6 M guanidine hydrochloride 
both at 290 nm with an extinction coefficient of 26,600 M−1cm−1 and at 280 nm with an 
extinction coefficient of 45,840 M−1cm−1 in a spectrophotometer (NanoDrop). Full-length 
human gelsolin was added to actin at a ratio of 1:1,000 to reduce the viscosity of the actin 
and thereby decrease pipetting error at higher actin concentrations without affecting the 
ATPase activity. The steady-state actin-activated ATPase activities of freshly prepared 
human beta-cardiac sS1-eGFP myosin using WT and KO actin were determined using a 
colorimetric readout of phosphate production57, as described in a previous work51. In this 
assay, reactions containing sS1 at a final concentration of 0.01 mg/ml, 2 mM ATP, and actin 
at concentrations ranging from 5 to 77 μM were performed at 23 °C with shaking using a 
microplate spectrophotometer (Thermo Scientific Multiskan GO). The rate of sS1 activity 
was obtained by linear fitting the phosphate signal as a function of time and converted to 
activity units using a phosphate standard. Each actin condition was performed in duplicate, 
The error on each data point represents the s.e.m. of the duplicates. The Michaelis–Menten 
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equation was fitted to determine the maximal activity (kcat) and the actin concentration at 
half-maximum (apparent Km for actin).
Statistics.
GraphPad Prism 7.0 or KaldeidaGraph 4.5 software were used for statistics.
Data availability.—The X-ray structures (coordinates and structure factor files) of SETD3 
with bound actin peptide have been submitted to PDB under accession number 6MBJ (P21), 
6MBK (Two complexes in P212121) and 6MBL (one complex in P212121). Source data for 
this study are provided as supplementary information (Fig. 4d, 5b, 5e, 5f, 5i, 5k; Extended 
Data Fig. 7e, 9c, 9h). Source gel data provided for cropped images (Fig. 1a, 1d, 1e, 2a, 2c, 
3a-f,g, 4c, 5g, 5j; Extended Data Fig. 1b) is provided in Supplementary Figure 1. Mass 
spectrometry data associated with Fig. 1c/Extended Data Fig. 1h and Fig. 3i are provided as 
a Supplementary Tables. Additional requests can be made to the corresponding authors.
Extended Data
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Extended Data Figure 1. Identification of actin as a SETD3 substrate.
a, Top: domain structure of SETD3 containing an N-terminal SET domain and a C-terminal 
domain homologous to plant Rubisco LSMT. Bottom: alignment of homologous 
methyltransferases human SETD3 and human SETD6. Red box, putative catalytic tyrosine. 
b, Methylation reactions as in Fig. 1a with non-radiolabeled SAM and analyzed by Western 
blot with indicated antibodies. Total H3 shown as a loading control. c, SETD3 localizes to 
the cytoplasm. Representative immunofluorescence images of GFP or GFP-SETD3 
localization in HeLa cells (left) are merged with DAPI counterstaining (right). Scale bar, 7 
μm. d-g, Biochemical enrichment of a candidate SETD3 substrate. d, Schematic of 
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biochemical strategy to identify methylated band indicated in Fig. 1b. e, in vitro methylation 
reactions using cell extracts separated by size-exclusion chromatography as a substrate. 
Reactions were performed with either wild-type (WT) SETD3 or a putative catalytic mutant 
(Y312A). Reactions were analyzed as in Fig. 1. Arrowhead, candidate substrate. f, Ion-
exchange chromatography separates candidate substrates. Fractions positive for SETD3-
specific methylation by size-exclusion chromatography were further separated by ion-
exchange chromatography and either the flowthrough (FT) or pooled fractions containing a 
significantly silver-stained band (arrowhead) at the size of the candidate substrate were used 
as substrate in an in vitro methylation reaction. g, Flowthrough (FT) or pooled eluent from 
ion-exchange chromatography were used as substrate for methylation reactions as in e. 
Arrowhead, protein band in eluent that was analyzed by mass spectrometry. h, Top candidate 
substrates with molecular weight (MW) similar to the size of SETD3-dependent band from 
in vitro reactions with cell extracts. Candidates identified by mass spectrometry are ranked 
by abundance determined by MS/MS count (Supplementary Table 1). i, in vitro methylation 
reactions with SETD3 on actin, recombinant histone H3 (rH3), FOXM1, or a no substrate as 
a control. Top panel, 3H-SAM is the methyl donor and methylation visualized by 
autoradiography. Bottom panel, Coomassie staining of proteins in the reaction. j, in vitro 
methylation reactions with the indicated enzymes and substrates. All experiments were 
repeated at least three times with similar results.
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Extended Data Figure 2. SETD3 does not methylate beta-actin lysines.
GST-beta-actin was expressed in bacteria, and cleaved using Prescission protease. Cleaved 
beta-actin was used in an in vitro methylation assay with SETD3 and deuterated SAM. 
Spectra are representative from experiments independently performed three times with 
similar results. MS/MS spectra with identified ions for unmethylated lysine residues 
produced with indicated proteases: a, K18 (trypsin) (Identified N-terminal GPLGS amino 
acids are residual, vector specific amino acids from the original GST fusion protein). b, K50 
(trypsin); c, K61 (trypsin); d, K68 (trypsin); e, K84 (chymotrypsin); f, K113 (trypsin); g, 
K118 (Glu-C); h, K191 (trypsin); i, K213 (trypsin); j, K215 (Glu-C); k, K238 
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(chymotrypsin); l, K284/K291 (chymotrypsin); m, K315/K326 (trypsin); n, K326/K328 
(trypsin); o, K336 (trypsin); p, K373 (trypsin).
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Extended Data Figure 3. SETD3 generates actin-H73(3-me).
a-c, Tandem MS/MS identifies H73 of actin as SETD3 methylated residue. a, Top: 
Methylated tryptic peptide with indicated b and y ions. Modifications: me, methylation; ox, 
oxidation. Bottom: Table of m/z for b and y ions identified in MS/MS spectra from 
methylation reactions with (+SETD3) or without (-SETD3) using deuterated SAM as the 
methyl donor (+17.03 Da mass shift). *, peptides containing H73. b-c, in vitro methylation 
reactions with (b) or without (c, negative control) SETD3 and beta-actin with deuterated S-
adenosyl-methionione (SAM) were analyzed by mass spectrometry. Left, MS/MS spectra of 
tryptic peptides containing H73. Right, b and y ions identified of oxidized (ox) peptides in 
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each spectrum are indicated. me, methylation. d, Dot blot loading control for Fig. 2c of 
biotinylated ACTB peptides (amino acids 66-80) that are unmodified at H73 or methylated 
in the N3 (3-me) or N1 (1-me) position. Serial dilutions of peptide were visualized by 
streptavidin-HRP and chemiluminescence. e-g, Methylation reaction kinetics for SETD3 and 
actin peptide. e, Time-course of SETD3 with His(1-me) or His(3-me) modified peptides as 
substrate. Inset: unmodified peptide using 80-fold lower enzyme concentration as that used 
for modified peptides. f-g, Steady-state kinetics of SETD3 for f, human beta-actin peptide 
(residues 66-80) and g, SAM. Kinetic measurements were performed using a bioluminescent 
methyltransferase assay, MTase-Glo™ (Promega). Means from biological triplicates for 
each data point are reported and error bars indicate standard deviation. a-g, Data are 
representative of three independent experiments with similar results.
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Extended Data Figure 4. Methylation of the conserved actin-H73 residue is present in diverse 
organisms.
a, Summary of actin histidine methylation on the conserved H73 residue among model 
organisms. Abundance of methylation is reported as a percent of peptide that is methylated. 
b, Chromatograms for MH3+ ions (m/z ± 10 ppm) for methylated and unmethylated versions 
of the indicated peptides. The unmethylated actin peptide that was analyzed for each species 
is shown above the corresponding chromatograms (ox, oxidation). When alpha-actin 
peptides were detected, associated chromatograms and quantification are provided on right. 
The area of indicated peaks was normalized to the sum area between peptides (± 
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methylation) and percent abundance is labeled. Chromatograms quantifying actin histidine 
methylation in human and mouse can be found in Extended Data Fig. 6 and 7. a-b, N.D., not 
detected. Quantification represents data from two independent experiments with similar 
results.
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Extended Data Figure 5. Structural details of SETD3-actin peptide interactions.
a, Overall structure of SETD3 with a V-shaped cleft constructed by the SET domain (green) 
and an LSMT-like domain (cyan). Helices are shown as cylinders and strands as arrows. 
Actin peptide shown as a stick model. b, View of the target histidine through the channel 
from the SAH binding pocket. c, Omit electron density of Fo-Fc, contoured at 3.0σ above 
the mean, is shown for omitting cofactor SAH and the actin peptide used for co-
crystallization. d, Details of inter- and intramolecular interactions between SETD3 (green) 
and actin peptide (yellow). e, W79 of actin bound in a hydrophobic surface pocket of 
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SETD3. f, T77 and N78 of actin form hydrogen bonds with N153 and Q254 of SETD3. g, 
V76 of actin is in van der Waals contact with SETD3 residues H323 and R315, which in turn 
interacts with E72 of actin. h, I75 of actin is in van der Waals contact with main-chain Cα of 
N255 and Q256 of SETD3. i, G74 of actin is located in the amino end of a SETD3 helix. 
The imidazole ring of H73 (the substrate target) is parallel with the aromatic ring of Y312 of 
SETD3. j, SETD3 R315 bridges between the carboxylate oxygen of E72 and the main-chain 
carbonyl oxygen of H73 of actin. k, I71 of actin is accommodated in a surface hydrophobic 
pocket of SETD3. l, Y69 and P70 of actin interact with a stretch of SETD3 residues from 
I283 to L289. m, Y69 of actin packs against P258 of SETD3 and K68 of actin interacts with 
E290 of SETD3. n, L67 and P70 of actin form an intra-molecular interaction and both 
interact with I283 and T284 of SETD3. o, Alignment of the amino acids from all six human 
actin isoforms corresponding to beta-actin amino acids 66-80. Variant amino acid 
highlighted in yellow. p, The cofactor (SAH) binding site includes residues R253, Y312, 
N277 and H278 of SETD3.
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Extended Data Figure 6. SETD3 is required for actin methylation in cells.
a, Peptide dot blot spotted with biotinylated beta-actin peptides (amino acids 66-80) 
containing H73, H73(3-me), or H73(1-me). Blots were probed with H73(3-me)-specific 
antibody or streptavidin as a loading control. b-d, Chromatograms for quantification of 
actin-H73me in human cells. Stoichiometry of oxidized beta/gamma-actin H73 peptide 
(YPIEHGIVTNWDDM(ox)EK) with or without methylation after purification from cells. 
MH3+ m/z: unmethylated, 654.968 ± 10 ppm; methylated, 659.6401 ± 10 ppm. Alpha-actin 
peptide was not detected in these cells. Quantification performed as in Extended Data Fig. 4. 
b, Chromatograms for HT1080 cells treated with CRISPR/Cas9 that is targeted with a 
control sgRNA or SETD3-specific sgRNAs. c, Chromatograms for actin H73 methylation in 
wild-type (WT) HeLa cells or clonal HeLa SETD3 knockout (KO) cells. N.D., not detected. 
d, Chromatograms of actin H73 methylation in HT1080 cells treated with CRISPR/Cas9 
targeted with a either a control or SETD3-specific sgRNA and complemented with CRISPR-
resistant SETD3WT, SETD3NHY or control plasmids. a-d, Experiments were performed 
three independent times with similar results.
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Extended Data Figure 7. SETD3 is required for actin-H73 methylation in mice.
a-d, Chromatograms for quantification of actin histidine methylation in mouse tissues. a, 
Chromatograms to determine abundance of histidine methylation from beta/gamma-actin 
H73 peptide (YPIEHGIVTNWDDM(ox)EK) with or without methylation after purification 
from brain tissue of mice with the indicated genotypes. MH3+ m/z: unmethylated, 654.968 
± 10 ppm; methylated, 659.640 ± 10 ppm. Alpha-actin peptide was not detected in these 
cells. Quantification performed as in Extended Data Fig. 4. b, Chromatograms to determine 
abundance of histidine methylation on alpha-actin H75 peptide 
(YPIEHGIITNWDDM(ox)EK) from skeletal muscle as in a. MH3+ m/z: unmethylated, 
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659.640 ± 10 ppm; methylated, 664.312 ± 10 ppm. Beta/gamma-actin peptide was not 
detected in these cells. c, Chromatograms to determine abundance of beta/gamma-actin H73 
methylation from uterine tissue as in a. d, Chromatograms to determine abundance of alpha-
actin H75 methylation from uterine tissue as in b. a-d, N.D., not detected. Quantification 
was performed three independent times with similar results. e, Table of quantitative amino 
acid panel from murine blood serum. Quantitative profiling of amino acids in plasma is used 
clinically to diagnose metabolic disorders. 3-methyl histidine (3MH) (indicated by asterisk) 
is one of the amino acids measured in the panel, and actin is thought to be the primary 
source of this metabolite. Setd3−/− (KO, n = 8) indicated amino acid levels were normalized 
to levels of amino acids from animals with normal H73 methylation levels (Total n = 12; 
Setd3+/+ (WT), n = 5; Setd3+/− (HET), n = 7). Standard error of the difference between two 
means is shown for the indicated n.
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Extended Data Figure 8. SETD3-dependent actin-H73 methylation modestly regulates 
polymerization.
a-b, Purification of actin with and without H73 methylation. a, Coomassie stained gel of the 
actin purified from HeLa cell lines described in Fig. 3f, Actin(+me) or Actin(-me), and used 
in biochemical assays described in Fig. 4a-b and c-e. b, Mass spectrometry quantification of 
actin H73 methylation from a. N.D., not detected. a-b, Representative data from an 
experiment performed at least three times with similar results. c, Methylation does not alter 
actin depolymerization rates. Actin polymerized as in Fig. 4a was diluted to 0.02 μM and 
depolymerization was monitored by fluorescence normalized to initial values. d, Elongation 
of the indicated monomeric actin (1 μM, 0.1 μM pyrene-actin) measured in the presence of 2 
μM phalloidin-actin seeds made with methylated (circles) or unmethylated (triangles). e, 
Arp2/3-induced actin polymerization performed in the presence of 100 nM WASP VCA and 
5 nM Arp2/3 complex with 1 μM of the indicated monomeric actin and 0.1 μM pyrene-actin. 
c-e, Mean values plotted with s.e.m. from three independent biological replicates. f, SETD3 
promotes cell migration. Representative images of cell migration assays performed three 
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times with similar results using cells from Fig. 4c. A circular void of cells was created at the 
start of the assay (0h, dashed red circle). After 24h of migration, cells were fixed and stained 
with DAPI. Scale bar, 100 μm.
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Extended Data Figure 9. Analysis of SETD3 and actin-H73me in parturition and uterine smooth 
muscle contraction.
a-b, Histology of muscle tissues from Setd3+/+ and Setd3−/− mice. a, Hematoxylin and eosin 
staining of aorta, colon, heart, tongue, and hind limb muscle from Setd3+/+ and Setd3−/− 
mice. b, Tongue and hind limb (striated muscle) sections from a were re-imaged without a 
condenser to highlight the sarcoplasmic striations characteristic of this muscle type. a-b, 
Scale bar: 20 μm. Images from three independent experiments gave similar results. c, 
Quantification of pups per litter for Setd3+/+ (n = 12), Setd3+/− (n = 43), Setd3−/− (n =26) 
mothers. ***, p-value = <0.001. d-e, Labor induction at 19 dpc does not rescue dystocia of 
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Setd3−/− pregnant mice. d, Schematic of prostaglandin treatment protocol. PGF2α cocktail 
was administered at 0, 3, and 8 hours on day 19 with euthanasia and quantification of fetuses 
at 32h after first treatment. e, Table quantifying births and postterm fetuses in utero for the 
indicated genotypes at the time shown in the schematic. Note: controls delivered before 
treatment commenced. f, Collagen contraction assay as in Fig. 5h with indicated 
reconstitution cell lines from Fig. 5j performed with three independent biological replicates. 
g-h, Actin-H73me does not notably alter myosin activity. g, in vitro actin motility assay. 
Gliding velocities of actin filaments prepared from actin described in Fig. 4 were measured 
using human β-cardiac sS1 myosin or a hyperactive mutant (H251N). Data are mean 
velocities with s.e.m. from four different experiments. h, Actin-activated ATPase of human 
β-cardiac sS1 using actin as in g. The Michaelis-Menten equation is fit to the ATPase data 
for WT actin (solid line) and KO actin (dashed line). Points are means from two independent 
experiments. For gel source data, see Supplementary Fig. 1.
Extended Data Table 1.
Summary of X-ray data collection from SERCAT beamline (22-ID) at wavelength = 1Å and 
refinement statistics. (*)
SETD3 Actin peptide
SAH
Actin peptide
SAH
Actin peptide
SAH
PDB Code 6MBJ 6MBK 6MBL
Data Collection
Space group P21 P212121 P212121
Cell dimensions (Å) 60.35, 176.17, 66.58 60.28, 115.97, 173.59 56.56, 92.83, 111.64
α, β, γ (°) 90, 92.9, 90 90, 90, 90 90, 90, 90
Resolution (Å) 39.07-1.79 (1.85-1.79) 39.38-1.69 (1.75-1.69) 48.30-2.19 (2.27-2.19)
a
 Rmerge 0.146 (0.892) 0.129 (0.800) 0.125 (0.741)
Rpim 0.041 (0.436) 0.061 (0.592) 0.066 (0.548)
CC1/2, CC (0.463, 0.795) (0.720, 0.915) (0.402, 0.757)
b
 <I/σI> 14.5 (1.0) 11.3 (1.7) 14.1 (1.5)
Completeness (%) 94.5 (78.9) 99.2 (98.4) 99.5 (96.7)
Redundancy 13.6 (8.0) 19.2 (8.9) 10.6 (4.7)
Observed reflections 1,695,347 2,597,462 323,060
Unique reflections 124,387 (10,380) 135,382 (13,262) 30,434 (2920)
Refinement
Resolution (Å) 1.79 1.69 2.19
No. reflections 123,743 135,110 30,334
c
 Rwork / d Rfree 0.199 / 0.223 0.228 / 0.243 0.182 / 0.227
No. Atoms Two complexes Two complexes One complex
Protein 7824 7953 3923
Peptide 248 252 124
SAH 52 52 26
Solvent 777 933 179
B-factors (Å2)
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SETD3 Actin peptide
SAH
Actin peptide
SAH
Actin peptide
SAH
PDB Code 6MBJ 6MBK 6MBL
Protein 34.3 29.6 47.3
Peptide 41.4 34.5 42.3
SAH 18.0 16.7 32.0
Solvent 45.2 39.9 46.5
R.m.s. deviations
Bond lengths (Å) 0.003 0.010 0.004
Bond angles (°) 0.564 0.942 0.683
Values in parenthesis correspond to highest resolution shell.
a
, Rmerge = Σ ∣ I - <I>∣ /Σ I, where I is the observed intensity and <I> is the averaged intensity from multiple observations.
b
, <I/σI> = averaged ratio of the intensity (I) to the error of the intensity (σI).
c
, Rwork = Σ ∣ Fobs - Fcal ∣ /Σ ∣ Fobs ∣, where Fobs and Fcal are the observed and calculated structure factors, respectively.
d
, Rfree was calculated using a randomly chosen subset (5%) of the reflections not used in refinement.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. SETD3 specifically methylates actin.
a, SETD3 does not methylate histones. in vitro methylation reactions on recombinant 
nucleosomes with recombinant SETD3, minimal MLL2 catalytic complex (MLL2c), 
catalytically active NSD2 SET domain, or glutathione-S-transferase (GST) as a control. Top 
panel, 3H-SAM is the methyl donor and methylation visualized by autoradiography. Bottom 
panel, Coomassie stain of nucleosomes used in the reaction. b, SETD3 methylates a 
cytoplasmic protein. in vitro methylation reactions as in a with recombinant SETD3 or a 
putative catalytic mutant (Y312A) on cytoplasmic HT1080 cellular extracts as substrate. 
Red arrow, candidate substrate. *, SETD3. c, Actin is selectively methylated by SETD3. 
Methylation assays as in a with SETD3 and the indicated recombinant candidate substrates. 
d, Methylation assays with SETD3 and SETD6 on actin and RelA. e, Methylation assays 
with the indicated SET domain PKMTs using recombinant beta-actin as a substrate. 
Experiments were independently performed ≥3 times with similar results. For gel source 
data, see Supplementary Fig. 1.
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Figure 2. SETD3 methylates actin at histidine 73.
a, in vitro methylation assay with recombinant wild-type beta-actin or H73A mutant. *, non-
specific bacterial contaminant. b, Histidine methylation: left, histidine; center, 3-(τ)-methyl 
histidine; right, 1-(π)-methyl histidine. c, SETD3 generates H73(3-me). in vitro methylation 
reactions with SETD3 on the indicated peptides visualized by autoradiography. a,c, 
Experiments were independently performed three times with similar results. d-h, The 
molecular basis for SETD3 recognition of actin. d, A long surface groove of the SET 
domain accommodates the actin peptide (stick model). Surface is colored blue for positive, 
red for negative, and white for neutral charges. e, A cut-through view of the SET domain 
illustrates cofactor SAH and actin peptide approaching from opposing faces and meeting in 
the middle of the active-site channel. f, A superimposition of SETD6 (showing the SAM and 
target lysine residue in magenta) and SETD3 bound with actin peptide showing residues 
immediately before and after His73. g, Close-up view of actin peptide binding groove with 
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side chains W79 and I71 inserted into two hydrophobic pockets (circled in red dashed lines). 
For gel source data, see Supplementary Fig. 1.
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Figure 3. SETD3 is the principal enzyme generating actin-H73me in cells and in vivo.
a, in vitro methylation assay with SETD3 on indicated structure-guided actin mutants. b, 
SETD3 methylation reactions on all human actin isoforms. c, Analysis of methylation 
activity of SETD3 mutants: Y312A, catalytic tyrosine; NHY, SAM-binding amino acids 
(N277A/H278A) + Y312A. d-e, SETD3 is necessary for H73 methylation in cells. d, 
Western blots with the indicated antibodies on HT1080 whole cell extracts (WCE) 
expressing CRISPR/Cas9 and two independent single guide RNAs (sgRNAs) targeting 
SETD3 or a control sgRNA. Actin levels do not change and tubulin is shown as a loading 
control. e, Western blots probing WCE made from HeLa cells or a clonal SETD3 knockout. 
f, Western blots of SETD3-deficient HT1080 cells as in e complemented with CRISPR-
resistant SETD3WT, SETD3NHY or control plasmids. g, SETD3 mediates actin H73 
methylation in vivo. Whole tissue extracts were made from the indicated tissues from 
Setd3+/+ and Setd3−/− mice and analyzed by Western blot. h, in vitro reactions with SETD3 
and SETD6 on purified beta-cardiac myosin sS1 (MYH7) and beta-actin as a positive 
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control. i, Methylation of actin-H73 is the only change out of >900 lysine, arginine, and 
histidine methylation events detected upon SETD3 depletion in cells. SILAC-based 
quantitative proteomic analysis of methylated peptides in cells ±SETD3 using HeLa cells 
from e. SILAC ratios from two independent experiments are plotted in the forward direction 
(x-axis, log2-transformed) and the label-swapped reverse direction (y-axis, -log2-
transformed). Forward: WT, light; SETD3 KO, heavy. Reverse: WT, heavy; SETD3 KO, 
light. SETD3-dependent methylation events are found in the top-right quadrant. For actin-
H73me, no heavy peptide was found in the forward direction due to complete loss of 
SETD3, so the ratio divisible by zero was plotted as infinite. An actin-H73me ratio is 
calculated in the reverse direction due to incomplete heavy amino acid labeling cross 
contamination. Experiments were independently performed three times with similar results. 
For gel source data, see Supplementary Fig. 1.
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Figure 4. H73 methylation regulates actin behavior.
a-b,. Methylation increases actin polymerization. a, Pyrene-labeled skeletal muscle actin 
was added to the indicated actin in a 1:10 ratio (pyrene:Hela actin) and polymerization was 
monitored by arbitrary fluorescence units (AFU) with 5 μM actin. b, ATP exchange rates 
decrease due to H73 methylation. Actin saturated with ε-ATP was monitored for exchange 
with normal ATP by loss of fluorescence over time. Exponential curves (dashed lines) were 
drawn to the data by least squares fitting. c-d, SETD3 promotes cell migration. c, Western 
blot analysis of whole cell extracts from mouse embryonic fibroblasts isolated from Setd3+/− 
and Setd3−/− mice. d, Quantification of cell migration assays (see methods) over a 24h 
period. *, p-value = 0.002; unpaired two-tailed student’s t-test. a-d, Graphs indicate the 
mean and s.e.m. from three independent biological replicates. All experiments 
independently repeated three times with similar results. For gel source data, see 
Supplementary Fig. 1.
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Figure 5. SETD3 regulates signal-induced smooth muscle contraction.
a-f, Primary dystocia in SETD3 deficient female mice. a, Percent of pregnant females with 
dystocia. Genotypes and n as noted. b, Fetuses remaining in utero were quantified at 20 dpc 
or 24h after giving birth for the indicated genotype. ***, p-value < 0.0001 from one-way 
ANOVA with Tukey’s multiple comparison test. c, Example of a Setd3−/− female 20 dpc 
from b that had not given birth to live pups. Arrows, uteri containing fetuses (R, 4 fetuses; L, 
3 fetuses). d-f Labor induction at 18 dpc does not rescue dystocia of Setd3−/− pregnant mice. 
d, Schematic of oxytocin treatment protocol. e, Quantification of births on d18 and d19 after 
oxytocin treatment from Setd3+/+ (n = 7) and Setd3−/− (n = 5) mice. *, p-value = 0.042; **, p 
-value = 0.012. f, Quantification of fetuses in utero of mice from e (Setd3+/+ , n = 4; 
Setd3−/−, n = 5). ***, p-value = < 0.001. e,f, p-values: unpaired two-tailed student’s t test. a-
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b,e-f; box and whisker parameters: center line, median; box limits, upper and lower 
quartiles; whiskers, maximum and minimum are indicated. g-k, Stimulus-induced 
contraction requires SETD3 and actin-H73me. g, Western blot analysis of primary uterine 
smooth muscle cells expressing CRISPR/Cas9 and control or SETD3-specific sgRNA. h, 
Representative images of a collagen contraction assay with cells from g ± oxytocin (OXT, 
10 μM) or Endothelin-1 (Eth-1, 1 μM) after 24h. i, Quantification of h. Collagen disk area is 
measured for indicated conditions and normalized to the area without cells. * p-value = 
0.019; **, p-value = 0.007. j, Western blot analysis of cells from g expressing SETD3WT, 
catalytically dead SETD3NHY, or a control vector. k, Quantification of contraction assays 
with reconstituted primary uterine cell lines as described in i. * p-value = 0.009; **, p-value 
= 0.006; ***, p-value = 0.001. g-k, Graphs indicate means with s.e.m. of experiments 
performed in biological triplicate. p-values from unpaired two-tailed student’s t-test. All 
experiments were independently performed three times with similar results. For gel source 
data, see Supplementary Fig. 1.
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